Federal Register · Regulatory notice
Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 34 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Follow PFE- Became public
- Jul 6, 2026
- Event / period date
- Not stated
- Collected
- Nov 7, 2026, 7:16 PM EST
Why this is connected
The source explicitly mentions PFIZER INC. A mention alone does not establish a financial benefit.
Source evidence
Read the source excerpt or record
---------------------------------- Application No. Drug Applicant ------------------------------------------------------------------------ NDA 007337.............. Percodan (aspirin; Endo Operations oxycodone Limited c/o Endo USA, hydrochloride (HCl)) Inc., 9 Great Valley Tablets, 325 Parkway, Malvern, PA milligrams (mg); 19355. 4.8355 mg. Percodan (aspirin; oxycodone HCl; oxycodone terephthalate) Tablets, 325 mg; 4.5 mg; 0.38 mg.. Percodan-Demi (aspirin; oxycodone HCl; oxycodone terephthalate) Tablets, 325 mg; 4.5 mg; 0.19 mg. NDA 017376.............. Septra Monarch (sulfamethoxazole; Pharmaceuticals, LLC trimethoprim) c/o Pfizer Inc., 66 Tablets, 80 mg; 400 Hudson Blvd. East, mg. New York, NY 10001. Septra DS (sulfamethoxazole; trimethoprim) Tablets, 160 mg; 800 mg.. NDA 017994.............. Psorcon E (diflorasone Pfizer Inc., 66 Hudson diacetate) Ointment, Blvd. East, New York, 0.05%. NY 10001. NDA 018701.............. Haldol (haloperidol Janssen decanoate) Pharmaceuticals, Injectable, Inc., c/o Janssen equivalent to (EQ) 50 Research and mg base/milliliter Development, 920 U.S. (mL) and EQ 100 mg Highway 202, P.O. Box base/mL. 300, Raritan NJ 08869- 0602. NDA 019151.............. Rythmol (propafenone GlaxoSmithKline LLC, HCl) Tablets, 150 mg, 2929 Walnut St., 225 mg, and 300 mg. Suite 1700, Philadelphia, PA 19104. NDA 019260.............. Psorcon (diflorasone Pfizer Inc., 66
Price change after we could observe it
+0.75% PFE
Adjusted closing prices from Nov 9, 2026 to Nov 11, 2026. SPY changed 0.95% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in PFE
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 25, 2026 · disclosed Oct 7, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 11, 2026 · disclosed Oct 7, 2026 · Dependent
- Oct 7, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
$1K–$15K · Traded Nov 26, 2024 · disclosed Aug 7, 2026 · filed 619 days later
Got $3K from the company’s PAC - Jul 21, 2026$50K–$100K
Sen. Alan Armstrong (R-OK)
$50K–$100K · Traded Mar 24, 2026 · disclosed Jul 21, 2026 · filed 119 days later
Committee overlap: HELP - Jul 16, 2026$15K–$50K
Sen. Tommy Tuberville (R-AL)
$15K–$50K · Traded Jun 8, 2026 · disclosed Jul 16, 2026 · Joint
Committee overlap: HELP - May 11, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Apr 13, 2026 · disclosed May 11, 2026 · Spouse
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.